NASDAQ:OCUL Ocular Therapeutix Q4 2025 Earnings Results & Report $7.51 +0.28 (+3.87%) Closing price 04:00 PM EasternExtended Trading$7.48 -0.04 (-0.47%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Ocular Therapeutix beat analyst earnings expectations but missed on revenue in its Q4 2025 results, released February 5, 2026. The company reported EPS of -$0.29 versus the -$0.33 consensus estimate, while revenue of $13.25 million fell short of the $16.13 million estimate by $2.88 million. Revenue decreased 22.4% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Ocular Therapeutix EPS ResultsActual EPS-$0.29Consensus EPS -$0.33Beat/MissBeat by +$0.04One Year Ago EPS-$0.29EPS Beat Rate3 of last 8 quartersOcular Therapeutix Revenue ResultsActual Revenue$13.25 millionExpected Revenue$16.13 millionBeat/MissMissed by -$2.88 millionYoY Revenue Growth-22.40%Upcoming EarningsOcular Therapeutix's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Ocular Therapeutix Q4 2025 Earnings FAQ Did Ocular Therapeutix beat earnings estimates for Q4 2025? Ocular Therapeutix (NASDAQ:OCUL) reported earnings of -$0.29 per share for Q4 2025, beating the consensus estimate of -$0.33. The report was announced on Thursday, February 5, 2026. What was Ocular Therapeutix's revenue for Q4 2025? Ocular Therapeutix reported revenue of $13.25 million for Q4 2025, against a consensus estimate of $16.13 million. When is Ocular Therapeutix's next earnings date? Ocular Therapeutix's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Ocular Therapeutix on the company's earnings history page. Ocular Therapeutix Earnings HeadlinesOcular Therapeutix (NASDAQ:OCUL) Stock: Insider Jeffrey Heier Sells 10,869 SharesOctober 8 at 5:08 AM | americanbankingnews.comOcular Therapeutix, Inc. (OCUL) Presents at Euretina 2026 - SlideshowOctober 6 at 7:03 PM | seekingalpha.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 8 at 1:00 AM | Porter & Company (Ad)Comparing Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)October 6 at 2:15 AM | americanbankingnews.comStocktwits Pharma Pulse: Roche faces FDA decision, gene-therapy stocks step into focus — the week’s biotech watchlistOctober 4, 2026 | msn.comOcular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from Chardan CapitalOctober 4, 2026 | americanbankingnews.comSee More Ocular Therapeutix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email. Email Address About Ocular TherapeutixOcular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based formulation and delivery technologies to create sustained-release treatments intended to improve drug delivery, reduce dosing frequency and address unmet needs in ophthalmology. Its commercial product is DEXTENZA, a corticosteroid ophthalmic insert that is placed in the canaliculus by a healthcare professional. DEXTENZA is approved in the United States for the treatment of ocular itching associated with allergic conjunctivitis and for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix is also advancing a pipeline of investigational treatments for retinal diseases and other ophthalmic conditions, including therapies designed for longer-duration drug delivery. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix primarily serves the U.S. ophthalmology market. The company is led by co-founder Antony P. Marucci, who serves as president and chief executive officer. Its products and development programs are supported by research, clinical development and commercial activities focused on the United States.View Ocular Therapeutix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
